CADTH Canadian Drug Expert Committee recommendation. AbobotulinumtoxinA (Dysport therapeutic -- Ipsen Biopharmaceuticals Canada Inc.) : indication: for the symptomatic treatment of focal spasticity affecting the upper limbs in adults.

CADTH Canadian Drug Expert Committee recommendation. indication: for the symptomatic treatment of focal spasticity affecting the upper limbs in adults. AbobotulinumtoxinA (Dysport therapeutic -- Ipsen Biopharmaceuticals Canada Inc.) :

Show other versions (7)

The CADTH Canadian Drug Expert Committee (CDEC) recommends that abobotulinumtoxinA (aboBoNTA, Dysport Therapeutic) be reimbursed for the symptomatic treatment of focal spasticity affecting the upper limbs in adults.

Saved in:

Bibliographic Details
Online Access:	http://www.ncbi.nlm.nih.gov/books/NBK534677/ Full text
Corporate Author:	CADTH Canadian Drug Expert Committee (Author)
Format:	Electronic eBook
Language:	English
Published:	Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017
Edition:	Version 1.0.
Series:	Common drug review clinical review report.
Subjects:	Muscle Spasticity > drug therapy. Upper Extremity > physiopathology. Botulinum Toxins, Type A > therapeutic use. Insurance, Health, Reimbursement > economics. Drug Costs. Cost-Benefit Analysis. Canada.

Description
Summary:	The CADTH Canadian Drug Expert Committee (CDEC) recommends that abobotulinumtoxinA (aboBoNTA, Dysport Therapeutic) be reimbursed for the symptomatic treatment of focal spasticity affecting the upper limbs in adults.
Item Description:	"Final."
Physical Description:	1 online resource (1 PDF file (7 pages)).
Source of Description, Etc. Note:	Description based on online resource; title from PDF title page (viewed March 8, 2019).
Funding Information Note:	Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.